SabinaSandigurskyMD

Rheumatology • New York, NY

Associate Medical Director

Join to view full profile

Dr. Sandigursky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sandigursky's full profile

Already have an account?

Office
160 East 34th Street
9th Floor
New York, NY 10016
Phone+1 212-731-5430

Summary

Rheumatologist with an interest in immunotoxicty working in early phase clinical trials for the treatment of malignancy using immune modulating drugs.

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2011 - 2014
St. George's University School of MedicineClass of 2011

Certifications & Licensure

NY State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Publications & Presentations

PubMed

2 citations
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A Lopez-Olivo, Houssein Safa
Oncoimmunology. 2023-01-01
6 citations
Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases.
Andrew Snavely, Eduardo J Pérez-Torres, Jeffrey S Weber, Sabina Sandigursky, Sujata P Thawani
Journal of the Neurological Sciences. 2022-07-15
2 citations
Toxicity and cosmetic outcome of breast irradiation in women with breast cancer and autoimmune connective tissue disease: the role of fraction and field size.
Juhi M. Purswani, Brian Jaros, Cheongeun Oh, Sabina Sandigursky, J. Xiao
Practical Radiation Oncology. 2021-11-10

Journal Articles

Review Targeting the Programmed Cell Death-1 Pathway in Rheumatoid Arthritis
Adam Mor, Greg J. Silverman, Sabina Sandigursky, ScienceDirect

Press Mentions

Initiating Guideline-Concordant Gout Treatment Improves Arterial Endothelial Function and Reduces Intercritical Inflammation: A Prospective Observational StudyJuly 11th, 2020
New Registry Focuses on Rheumatic Immune-Related AEs of Cancer TherapyJune 18th, 2020
Study Shows Promise in Immunotherapy for Rheumatoid ArthritisNovember 22nd, 2019
Join now to see all

Industry Relationships

Associate Medical Director, Regeneron pharmaceuticals2020 - Present